The new IP battleground in CRISPR-Cas

While much attention has been focused on the major IP battle affecting foundational patents covering CRISPR-Cas9 systems as gene modifiers, another battle has erupted concerning modified guide ribonucleic acids (RNAs) for use with Cas enzymes. The most visible recent sign of this was the invalidation of all claims of two US Patents of Agilent, US10,900,034 and US10,337,001, by a Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) in inter partes review proceedings instigated by Synthego.